--

Professor Tobias Arkenau is a renowned Consultant Medical Oncologist with HCA Healthcare at numerous locations including Sarah Cannon Research Institute, The Harley Street Clinic, The Princess Grace and The Wellington Hospital. Additionally, he holds an NHS post at University College London Hospital where he is a Professorial Research Associate.

He is a founding Medical Director of the Sarah Cannon Research Institute UK and is currently serving as the Executive Medical Director for SCRI UK and Clinical Lead for the HCA Healthcare UK Cancer Service Line. The talented physician has a wide range of experience in a variety of cancers, particularly gastrointestinal and skin cancers.

He was awarded his medical degree from Hanover Medical School in Germany in 2000. Following this, he completed his specialist training in oncology across numerous centres of excellence including the Royal Marsden Hospital. He was awarded a Fellowship by the Royal College of Physicians, and he is a key opinion leader in his field of Gastrointestinal Cancers, Drug Development and Immunotherapy for his research contributions to his field. During his career, he has published numerous peer reviewed articles and book chapters and contributes regularly at international meetings such as ASCO, ESMO and AACR. He is leading the Sarah Cannon Institute UK as a Chief and Principal Investigator of numerous clinical trials of new anti-cancer drugs including immunotherapies and cellular therapies.

Professor Arkenau has expertise in the following areas:

• Immunotherapy
• Chemotherapy
• Clinical Trials, Phase-1 studies
• Drug Development, Experimental Therapies
• TIL-Therapy
• Biological Therapy
• Video Consultation
• Genetic Testing (Genomics Review Board)
• Gastrointestinal Cancer
• Skin Cancer
• Upper Gastrointestinal Cancer
• Lower Gastrointestinal Cancer
• Melanoma
• Bile Duct Cancer
• Bowel Cancer
• Colon Cancer
• Gallbladder Cancer
• Liver Cancer
• Oesophagus Cancer
• Pancreatic Cancer
• Stomach Cancer
• Small Bowel Cancer